Aclaris Therapeutics completes enrollment for Phase 2 atopic dermatitis trial
Aclaris Therapeutics (NASDAQ:ACRS) announced it has successfully completed patient enrollment for its Phase 2 clinical trial of bosakitug (ATI-045), an investigational treatment for patients suffering from moderate-to-severe atopic dermatitis.





_1362080_640x360_2492579907807-640x360.webp&w=3840&q=75)





_1361993_640x360_2492576323858-640x360.webp&w=3840&q=75)